Found: 18
Select item for more details and to access through your institution.
Dasatinib plus Peg‐Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA‐PegIFN study).
- Published in:
- British Journal of Haematology, 2023, v. 200, n. 2, p. 175, doi. 10.1111/bjh.18486
- By:
- Publication type:
- Article
Real-world therapeutic response and tyrosine kinase inhibitor discontinuation in chronic phase-chronic myeloid leukemia: data from the French observatory.
- Published in:
- Annals of Hematology, 2022, v. 101, n. 10, p. 2241, doi. 10.1007/s00277-022-04955-z
- By:
- Publication type:
- Article
The Spliceosome: A New Therapeutic Target in Chronic Myeloid Leukaemia.
- Published in:
- Cancers, 2022, v. 14, n. 19, p. 4695, doi. 10.3390/cancers14194695
- By:
- Publication type:
- Article
Red blood cell transfusion burden in myelodysplastic syndromes (MDS) with ring Sideroblasts (RS): A retrospective multicenter study by the Groupe Francophone des Myélodysplasies (GFM).
- Published in:
- Transfusion, 2022, v. 62, n. 5, p. 961, doi. 10.1111/trf.16884
- By:
- Publication type:
- Article
Combination of PKCδ Inhibition with Conventional TKI Treatment to Target CML Models.
- Published in:
- Cancers, 2021, v. 13, n. 7, p. 1693, doi. 10.3390/cancers13071693
- By:
- Publication type:
- Article
Efficacy of lenalidomide in myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and an extreme platelet count.
- Published in:
- Clinical Case Reports, 2020, v. 8, n. 9, p. 1774, doi. 10.1002/ccr3.3026
- By:
- Publication type:
- Article
Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome.
- Published in:
- British Journal of Haematology, 2019, v. 187, n. 3, p. 337, doi. 10.1111/bjh.16083
- By:
- Publication type:
- Article
Using healthcare claims data to analyze the prevalence of BCR‐ABL‐positive chronic myeloid leukemia in France: A nationwide population‐based study.
- Published in:
- Cancer Medicine, 2019, v. 8, n. 6, p. 3296, doi. 10.1002/cam4.2200
- By:
- Publication type:
- Article
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Lymphocytes NK : un rôle majeur dans le contrôle immunologique de la leucémie myéloïde chronique.
- Published in:
- Médecine Sciences, 2018, v. 34, n. 6/7, p. 540, doi. 10.1051/medsci/20183406013
- By:
- Publication type:
- Article
DNA methylation profiling reveals a pathological signature that contributes to transcriptional defects of CD34<sup>+</sup>CD15<sup>−</sup> cells in early chronic‐phase chronic myeloid leukemia.
- Published in:
- Molecular Oncology, 2018, v. 12, n. 6, p. 814, doi. 10.1002/1878-0261.12191
- By:
- Publication type:
- Article
Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis.
- Published in:
- British Journal of Haematology, 2016, v. 175, n. 5, p. 975, doi. 10.1111/bjh.13902
- By:
- Publication type:
- Article
Impact of ELN recommendations in the management of first-line treated chronic myeloid leukaemia patients: a French cross-sectional study.
- Published in:
- British Journal of Haematology, 2016, v. 174, n. 1, p. 71, doi. 10.1111/bjh.14022
- By:
- Publication type:
- Article
Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up.
- Published in:
- Cancer (0008543X), 2015, v. 121, n. 10, p. 1637, doi. 10.1002/cncr.29240
- By:
- Publication type:
- Article
Outcomes in RBC transfusion-dependent patients with Low-/ Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study.
- Published in:
- European Journal of Haematology, 2014, v. 93, n. 5, p. 429, doi. 10.1111/ejh.12380
- By:
- Publication type:
- Article
Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/ II Study by the GFM.
- Published in:
- British Journal of Haematology, 2012, v. 158, n. 2, p. 232, doi. 10.1111/j.1365-2141.2012.09153.x
- By:
- Publication type:
- Article
Sideroblastic anemia: molecular analysis of the ALAS2 gene in a series of 29 probands and functional studies of 10 missense mutations.
- Published in:
- Human Mutation, 2011, v. 32, n. 6, p. 590, doi. 10.1002/humu.21455
- By:
- Publication type:
- Article